Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
1.850
+0.050 (2.78%)
At close: Apr 28, 2026, 4:00 PM EDT
1.850
0.00 (0.00%)
After-hours: Apr 28, 2026, 8:00 PM EDT
Serina Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 0.13 | 0.06 | 3.15 | 0.59 | 3.46 |
| Revenue Growth (YoY) | 132.14% | -98.22% | 433.05% | -82.93% | - |
| Cost of Revenue | 13.16 | 7.48 | 2.39 | 1.57 | 3.8 |
| Gross Profit | -13.03 | -7.42 | 0.77 | -0.98 | -0.33 |
| Selling, General & Admin | 11 | 8.15 | 2.3 | 1.29 | 1.3 |
| Operating Expenses | 11 | 8.15 | 2.3 | 1.29 | 1.3 |
| Operating Income | -24.02 | -15.57 | -1.53 | -2.27 | -1.63 |
| Interest Expense | -0.21 | -0.53 | -0.56 | -0.02 | -0 |
| Interest & Investment Income | - | - | - | 0 | 0.01 |
| Other Non Operating Income (Expenses) | 5.04 | 13.38 | 1.36 | -0.12 | 0.21 |
| EBT Excluding Unusual Items | -19.2 | -2.71 | -0.73 | -2.41 | -1.42 |
| Merger & Restructuring Charges | - | -1.48 | -1.6 | - | - |
| Gain (Loss) on Sale of Investments | - | - | - | -0.01 | -0.01 |
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.03 |
| Other Unusual Items | - | -7.02 | 7.6 | -0.27 | 0.19 |
| Pretax Income | -19.2 | -11.21 | 5.27 | -2.68 | -1.26 |
| Income Tax Expense | 0.02 | - | - | - | - |
| Earnings From Continuing Operations | -19.22 | -11.21 | 5.27 | -2.68 | -1.26 |
| Minority Interest in Earnings | 0.03 | 0.07 | - | - | - |
| Net Income | -19.18 | -11.14 | 5.27 | -2.68 | -1.26 |
| Preferred Dividends & Other Adjustments | 0.25 | - | - | - | - |
| Net Income to Common | -19.44 | -11.14 | 5.27 | -2.68 | -1.26 |
| Shares Outstanding (Basic) | 10 | 7 | 2 | 2 | 2 |
| Shares Outstanding (Diluted) | 10 | 7 | 7 | 2 | 2 |
| Shares Change (YoY) | 38.47% | 0.11% | 242.70% | 0.01% | - |
| EPS (Basic) | -1.91 | -1.51 | 2.36 | -1.25 | -0.59 |
| EPS (Diluted) | -1.91 | -1.51 | 0.72 | -1.25 | -0.59 |
| Free Cash Flow | -18.01 | -17.16 | -2.98 | -2.09 | -2.34 |
| Free Cash Flow Per Share | -1.77 | -2.33 | -0.41 | -0.97 | -1.09 |
| Gross Margin | - | - | 24.26% | -165.95% | -9.63% |
| Operating Margin | -18478.46% | -27807.14% | -48.52% | -383.83% | -47.09% |
| Profit Margin | -14950.77% | -19894.64% | 167.11% | -453.44% | -36.50% |
| Free Cash Flow Margin | -13856.92% | -30641.07% | -94.51% | -352.55% | -67.41% |
| EBITDA | -23.95 | -15.38 | -1.44 | -2.21 | -1.6 |
| EBITDA Margin | - | - | -45.67% | - | -46.13% |
| D&A For EBITDA | 0.07 | 0.19 | 0.09 | 0.06 | 0.03 |
| EBIT | -24.02 | -15.57 | -1.53 | -2.27 | -1.63 |
| EBIT Margin | - | - | -48.52% | - | -47.09% |
| Revenue as Reported | 0.13 | 0.06 | 3.15 | 0.59 | 3.46 |
Source: S&P Capital IQ. Standard template.
Financial Sources.